A receptor that switches on inflammation inside the brain can be blocked with an existing drug, according to work led by Professor Nicholas Barnes at the University of Birmingham and published in the journal Brain. The target is the P2X7 receptor, which the team found drives the release of cytokines, the signalling proteins that control inflammatory responses. Treating human brain tissue with a specific P2X7 antagonist significantly reduced that inflammatory response.
What sets this study apart is the material it was done in. Rather than relying on animal models or cell lines, the researchers worked with live cultures of human brain cells and slices of brain tissue taken during neurosurgery. The team describes it as first-of-its-kind work in human tissue, which matters because inflammatory pathways do not always behave identically across species, and drugs that calm neuroinflammation in rodents have a long history of disappointing in people.
Neuroinflammation sits behind a broad range of brain conditions, and the Birmingham group frames its findings accordingly. Traumatic brain injury, neurodegenerative diseases including Alzheimer's and Parkinson's, and psychiatric conditions such as depression and psychosis are all now understood to carry an inflammatory component. A drug that already exists and can dampen the pathway in human brain tissue is a more practical starting point than building a new compound from scratch.
The gap between reducing cytokine release in tissue slices and slowing disease in patients remains wide. What this work establishes is that the pathway is active and druggable in human brain tissue - the next question is whether blocking it in living patients changes the course of any of these conditions.